DelveInsight’s, “Apolipoprotein C-III Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Apolipoprotein C-III Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Apolipoprotein C-III Inhibitors: Overview
Apolipoprotein C-III (APOC3) is a key regulator of lipoprotein metabolism and plays a pivotal role in regulating plasma triglyceride levels. It is synthesized principally in the liver and is a component of triglyceride-rich lipoproteins. It is known to inhibit lipoprotein lipase–mediated hydrolysis of triglyceride-rich lipoproteins and to adversely affect receptor-mediated hepatic uptake of remnants of triglyceride-rich lipoproteins.
The companies and academics are working to assess challenges and seek opportunities that could influence Apolipoprotein C-III Inhibitors R&D. The therapies under development are focused on novel approaches for Apolipoprotein C-III Inhibitors.
This segment of the Apolipoprotein C-III Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Apolipoprotein C-III Inhibitors Emerging Drugs
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. People with severely elevated triglycerides, such as people with familial chylomicronemia syndrome (FCS), are at high risk for acute pancreatitis and other serious conditions. ApoC-III is also the target of WAYLIVRA, the first approved medicine for patients with FCS.
ARO-APOC3: Arrowhead Pharmaceuticals,
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.
Further product details are provided in the report……..
This segment of the report provides insights about the different Apolipoprotein C-III Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the Apolipoprotein C-III Inhibitors. The companies which have their Apolipoprotein C-III Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Apolipoprotein C-III Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Apolipoprotein C-III Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Apolipoprotein C-III Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Apolipoprotein C-III Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Apolipoprotein C-III Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ARO APOC3: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ARGX 116: argenx
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Apolipoprotein C-III Inhibitors Key Companies
Apolipoprotein C-III Inhibitors Key Products
Apolipoprotein C-III Inhibitors- Unmet Needs
Apolipoprotein C-III Inhibitors- Market Drivers and Barriers
Apolipoprotein C-III Inhibitors- Future Perspectives and Conclusion
Apolipoprotein C-III Inhibitors Analyst Views
Apolipoprotein C-III Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Apolipoprotein C-III Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Apolipoprotein C-III Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Ionis Pharmaceuticals
• Arrowhead Pharmaceuticals
• argenx
• Korea United Pharm I
